AstraZeneca plc (AZN) Rating Reiterated by Liberum Capital
Liberum Capital reissued their buy rating on shares of AstraZeneca plc (LON:AZN) in a research note published on Thursday morning. The firm currently has a GBX 5,500 ($71.65) target price on the biopharmaceutical company’s stock.
Several other equities research analysts have also recently issued reports on AZN. Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($50.81) price objective on shares of AstraZeneca plc and gave the stock a sell rating in a research report on Wednesday, March 29th. Shore Capital reissued a sell rating on shares of AstraZeneca plc in a research report on Sunday, April 2nd. Beaufort Securities reissued a hold rating on shares of AstraZeneca plc in a research report on Monday, April 3rd. BNP Paribas reissued a neutral rating and issued a GBX 5,300 ($69.05) price target on shares of AstraZeneca plc in a research report on Monday, April 3rd. Finally, UBS AG set a GBX 5,150 ($67.09) price target on shares of AstraZeneca plc and gave the company a neutral rating in a research report on Wednesday, April 5th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of Hold and an average target price of GBX 5,085.05 ($66.25).
The firm also recently disclosed a dividend, which will be paid on Monday, September 11th. Stockholders of record on Thursday, August 10th will be given a GBX 68.90 ($0.90) dividend. This represents a dividend yield of 1.35%. The ex-dividend date of this dividend is Thursday, August 10th.
In other AstraZeneca plc news, insider Nazneen Rahman acquired 39 shares of the company’s stock in a transaction dated Thursday, July 27th. The stock was bought at an average price of GBX 4,370 ($56.93) per share, with a total value of £1,704.30 ($2,220.30).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.